Navigation Links
Vaccine shows therapeutic promise against advanced melanoma
Date:6/1/2009

ORLANDO - A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.

The findings, presented today at the American Society of Clinical Oncology (ASCO), mark the first vaccine study in the disease - and one of the first in cancer overall - to show clinical benefit in a randomized Phase III clinical trial. Patrick Hwu, M.D., professor and chair of M. D. Anderson's Department of Melanoma Medical Oncology, presented the findings on ASCO's press program.

According to the American Cancer Society, melanoma has one of the fastest growing incidence rates of all cancers. In 2009, more than 68,720 people in the U.S. are projected to be diagnosed with melanoma and 8,650 will likely die from the disease. The five-year survival rates for those with regional and metastatic disease are 65 percent and 16 percent, respectively.

"Obviously, this is a disease, in its advanced setting, in need of better therapies for our patients," said Hwu, a co-investigator on the study. "While more follow up is needed, this study serves as a proof-of-principle for vaccines' role in melanoma and in cancer therapy overall. If we can use the body's own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue."

During their tenure at the National Cancer Institute (NCI), Hwu and Douglas Schwartzentruber, M.D., who is currently medical director of the Goshen Center for Cancer Care, were involved in the vaccine's development and early basic and clinical studies. The peptide vaccine, known as gp100:209-217 (200M), works by stimulating patients' T cells, known for controlling immune responses.

"This vaccine activates the body's cytotoxic T cells to recognize antige
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaccine shows therapeutic promise against advanced melanoma
(Date:3/2/2015)... CA (PRWEB) March 02, 2015 Gummy ... gum reshaping procedures. Gum reshaping can involve one or several ... to regenerate lost gum tissue for a more even gum ... dark gum line treatment that can permanently lighten discolored ... total smile approach, which involves a personalized treatment plan to ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service offers ... Platinum Resistance Thermometers (SSPRTs) and industrial Resistance Temperature ... . . . guaranteed. Their metrology ... 200706-0), ISO 9001 and 17025 Certified and provides ... to 500°C, both ITS-90 and Callendar-van Dusen calibrations ...
(Date:3/2/2015)... 2015 Over the last five years ... vendors seeking to expand their geographic presence and achieve ... to reach $6.2 billion by 2019 at CAGR of ... the U.S. and Canada and a major part of ... regions such as Asia-Pacific including China and India, Latin ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual awareness ... people across the country to unite, raise awareness, ... their best lives. MS Awareness Week is a special week ... the Society’s vision of a world free of MS. ... the central nervous system, interrupts the flow of information within ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased ... Health Plans: 2015 , the all-new 12th edition of ... plan market, with enrollment data and contact information for ... Available as a printed book containing the full directory ... tables and charts, as well as an electronic version, ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2
... users were informed of their odds for cardiovascular ... Letting patients know how cholesterol boosts their heart ... researchers report. , Researchers at McGill University in ... the study) with cholesterol problems who were instructed ...
... In the very first trial of its kind in ... find out if water softeners can help in the ... by clinicians at The University of Nottingham has received ... National Institute for Health Research (NIHR) Health Technology Assessment ...
... , McGill University researchers have uncovered the crucial role ... onset of breast cancer. The research, led by Dr. William ... Institute for Cancer Research in Scotland was published the ... Academy of Sciences (PNAS). The study,s first author is Dr. ...
... Net Income Increases 22% and Royalty Income Increases 29% ... ... Unilens Vision Inc. (OTC,Bulletin Board: UVICF) (TSX Venture Exchange: UVI), ... operating results for the first quarter of FY2008., Net sales, ...
... Switzerland, November 29 Biolytix AG,( http://www.biolytix.ch ... UK Ltd ( http://www.affymetrix.com ) and offers ... R&D community under conditions,compliant with a stringent ... the leading CRO,s for molecular biological analysis ...
... 29 BlueCross BlueShield of South,Carolina and ... have,streamlined access to international dental services through ... Healthcare Inc., Earlier this year, Companion ... members access to medical and surgical treatment,at ...
Cached Medicine News:Health News:Knowing Heart Risk Keeps Patients on Cholesterol Drugs 2Health News:Eczema sufferers test out benefits of water softeners 2Health News:Eczema sufferers test out benefits of water softeners 3Health News:McGill researchers link enzyme to breast cancer malignancy 2Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4Health News:Biolytix to Offer Industrial Gene Expression Analysis and Genotyping Services Using Affymetrix' GeneChip(R) Technology 2Health News:S.C. BlueCross, BlueChoice HealthPlan Expand Global Offerings to Include Dental Services 2
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
West lacrimal cannula blunt tip with side port....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Shahinian lacrimal cannula, bullet shaped tip, 0.3 mm side opening, straight....
Medicine Products: